96TH GENERAL ASSEMBLY
State of Illinois
2009 and 2010
SB0771


 
Introduced 2/6/2009, by Sen. John J. Cullerton
 
SYNOPSIS AS INTRODUCED:
 		













305 ILCS 5/5-5.12
  from Ch. 23, par. 5-5.12







    Amends the Illinois Public Aid Code.  Makes a technical change in a
Section concerning pharmacy payments under the Medicaid program.
















LRB096 06838 DRJ 16924 b

















 


 


A BILL FOR









 











SB0771

LRB096 06838 DRJ 16924 b






1
    AN ACT concerning public aid.

 
2
    Be it enacted by the People of the State of Illinois, 
3
represented in the General Assembly: 

 
4
    Section 5. The Illinois Public Aid Code is amended by 
5
changing Section 5-5.12 as follows:
 



6
    (305 ILCS 5/5-5.12)  (from Ch. 23, par. 5-5.12)



7
    Sec. 5-5.12. Pharmacy payments. 

8
    (a) Every request submitted by a pharmacy for reimbursement 
9
under this
Article for prescription drugs provided to a 
10
recipient of aid under this
Article shall include the
the name 
11
of the prescriber or an acceptable
identification number as 
12
established by the Department.
13
    (b) Pharmacies providing prescription drugs under
this 
14
Article shall be reimbursed at a rate which shall include
a 
15
professional dispensing fee as determined by the Illinois

16
Department, plus the current acquisition cost of the 
17
prescription
drug dispensed. The Illinois Department shall 
18
update its
information on the acquisition costs of all 
19
prescription drugs
no less frequently than every 30 days. 
20
However, the Illinois
Department may set the rate of 
21
reimbursement for the acquisition
cost, by rule, at a 
22
percentage of the current average wholesale
acquisition cost.

23
    (c) (Blank).

 


 






SB0771
- 2 -
LRB096 06838 DRJ 16924 b




1
    (d) The Department shall not impose requirements for prior 
2
approval
based on a preferred drug list for anti-retroviral, 
3
anti-hemophilic factor
concentrates,
or
any atypical 
4
antipsychotics, conventional antipsychotics,
or 
5
anticonvulsants used for the treatment of serious mental

6
illnesses
until 30 days after it has conducted a study of the 
7
impact of such
requirements on patient care and submitted a 
8
report to the Speaker of the
House of Representatives and the 
9
President of the Senate.

10
(Source: P.A. 93-106, eff. 7-8-03; 94-48, eff. 7-1-05.)